Clinical Trial Update: Forodesine in the Treatment of Cutaneous T-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating forodesine for Cutaneous T-cell lymphoma has completed, as reported in a BioCryst-sponsored update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma

Drugs mentioned

• Forodesine (forodesine)

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Cutaneous T-cell Lymphoma (CTCL), | Phase 2 | Status: COMPLETED